*ST东洋(002086) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥91,870,508.63, a decrease of 42.72% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was -¥30,246,119.51, representing a decline of 300.96% year-on-year[5]. - Basic earnings per share for Q3 2023 were -¥0.04, a decrease of 300% compared to the same period last year[5]. - Total revenue for the third quarter was CNY 325,223,918.74, a decrease of 31.2% compared to CNY 472,878,051.32 in the same period last year[19]. - The net profit for Q3 2023 was -52,226,787.13 CNY, compared to -14,899,137.57 CNY in Q3 2022, indicating a significant decline in profitability[20]. - Operating profit for Q3 2023 was -52,048,493.19 CNY, a decrease from 29,714,570.04 CNY in the same period last year[20]. - Total comprehensive income for Q3 2023 was -49,645,100.66 CNY, compared to -6,714,367.22 CNY in Q3 2022[21]. - Basic and diluted earnings per share for Q3 2023 were both -0.07 CNY, down from -0.02 CNY in the previous year[21]. Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was -¥72,796,433.81, down 106.80% compared to the previous year[5]. - The company's cash and cash equivalents decreased to CNY 93,196,878.94 from CNY 129,788,588.18 at the beginning of the year, representing a decline of 28.2%[15]. - Cash and cash equivalents at the end of Q3 2023 were 91,731,639.17 CNY, down from 144,883,469.57 CNY at the end of Q3 2022[23]. - Total assets at the end of Q3 2023 were ¥2,049,068,466.24, an increase of 2.35% from the end of the previous year[5]. - Total assets increased to CNY 2,049,068,466.24 from CNY 2,001,961,772.53, marking a growth of 2.4%[17]. Liabilities and Equity - The total equity attributable to shareholders decreased by 4.22% from the end of the previous year, amounting to -¥1,217,264,156.53[5]. - Total liabilities rose to CNY 3,252,591,611.96, compared to CNY 3,155,839,817.59, an increase of 3.1%[17]. Operational Challenges - The company reported a significant decrease in revenue from testing fees and reagent kit sales, which contributed to the overall decline in performance[9]. - The company incurred credit impairment losses of -45,290,840.24 CNY in Q3 2023, compared to -31,946,697.59 CNY in Q3 2022[20]. - Interest expenses increased to 44,094,472.97 CNY in Q3 2023 from 40,327,272.39 CNY in the same period last year[20]. Restructuring and Future Outlook - The company is currently undergoing a pre-restructuring process, with uncertainty regarding the acceptance of the restructuring application by the court[13]. - The company has not provided specific guidance for future performance due to ongoing restructuring uncertainties[13]. - The company has not identified any other items that meet the definition of non-recurring gains and losses[8]. - The company has not undergone an audit for the Q3 2023 report[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,733[11].